Literature DB >> 19362281

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

Jamie Wagner1, Judy C Boughey, Betsy Garrett, Gildy Babiera, Henry Kuerer, Funda Meric-Bernstam, Eva Singletary, Kelly K Hunt, Lavinia P Middleton, Isabelle Bedrosian.   

Abstract

BACKGROUND: Optimal surgical management of patients with invasive lobular carcinoma (ILC) who undergo neoadjuvant chemotherapy (NAC) is unknown. We evaluated optimal margin distance and local recurrence (LR) rates for these patients.
METHODS: Ninety-three (30%) of 311 patients with ILC received NAC. We examined margin status, residual disease after re-excision, and clinical outcomes.
RESULTS: Margin positivity rates after the final operative procedure were similar between the NAC and surgery-first group (P > .05). The proportion of patients, stratified by margin status, who were taken back for re-excision was not different between the 2 groups, and, similarly, there were no differences in frequency of residual disease (all P > .05). At a median follow-up of 3.1 years, 1 patient in the NAC group and 2 in the surgery-first group developed LR (P = 1.0).
CONCLUSIONS: Patients with ILC who have undergone NAC and have margins >1 mm have a low probability of residual disease and LR.

Entities:  

Mesh:

Year:  2009        PMID: 19362281      PMCID: PMC4355914          DOI: 10.1016/j.amjsurg.2009.01.006

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  17 in total

1.  Margin status and the risk of local recurrence after breast-conserving treatment of lobular breast cancer.

Authors:  N van den Broek; M J C van der Sangen; L V van de Poll-Franse; M W P M van Beek; G A P Nieuwenhuijzen; A C Voogd
Journal:  Breast Cancer Res Treat       Date:  2006-11-18       Impact factor: 4.872

2.  Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma.

Authors:  Thao N Vo; Funda Meric-Bernstam; Min Yi; Thomas A Buchholz; Frederick C Ames; Henry M Kuerer; Isabelle Bedrosian; Kelly K Hunt
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

3.  Conservative surgery for infiltrating lobular breast carcinoma.

Authors:  B Salvadori; E Biganzoli; P Veronesi; R Saccozzi; F Rilke
Journal:  Br J Surg       Date:  1997-01       Impact factor: 6.939

4.  Role of conservation therapy for invasive lobular carcinoma of the breast.

Authors:  M Bouvet; D W Ollila; K K Hunt; G V Babiera; F R Spitz; A E Giuliano; E A Strom; F C Ames; M I Ross; S E Singletary
Journal:  Ann Surg Oncol       Date:  1997-12       Impact factor: 5.344

5.  Resection margin status in lumpectomy specimens of infiltrating lobular carcinoma.

Authors:  K T Mai; H M Yazdi; P A Isotalo
Journal:  Breast Cancer Res Treat       Date:  2000-03       Impact factor: 4.872

6.  Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution.

Authors:  M Tubiana-Hulin; D Stevens; S Lasry; J M Guinebretière; L Bouita; C Cohen-Solal; P Cherel; J Rouëssé
Journal:  Ann Oncol       Date:  2006-06-01       Impact factor: 32.976

7.  The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy.

Authors:  G Peiro; B A Bornstein; J L Connolly; R Gelman; S Hetelekidis; A J Nixon; A Recht; B Silver; J R Harris; S J Schnitt
Journal:  Breast Cancer Res Treat       Date:  2000-01       Impact factor: 4.872

8.  Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.

Authors:  Massimo Cristofanilli; Ana Gonzalez-Angulo; Nour Sneige; Shu-Wan Kau; Kristine Broglio; Richard L Theriault; Vicente Valero; Aman U Buzdar; Henry Kuerer; Thomas A Buchholz; Thomas A Buccholz; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

9.  Surgical treatment for invasive lobular carcinoma of the breast.

Authors:  M Hussien; T F Lioe; J Finnegan; R A J Spence
Journal:  Breast       Date:  2003-02       Impact factor: 4.380

10.  Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy.

Authors:  Robin M Ciocca; Tianyu Li; Gary M Freedman; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2008-05-28       Impact factor: 5.344

View more
  6 in total

1.  Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.

Authors:  Judy C Boughey; Jamie Wagner; Betsy J Garrett; Lori Harker; Lavinia P Middleton; Gildy V Babiera; Funda Meric-Bernstam; Anthony Lucci; Kelly K Hunt; Isabelle Bedrosian
Journal:  Ann Surg Oncol       Date:  2009-03-12       Impact factor: 5.344

2.  Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.

Authors:  Marieke E M van der Noordaa; Ileana Ioan; Emiel J Rutgers; Erik van Werkhoven; Claudette E Loo; Rosie Voorthuis; Jelle Wesseling; Japke van Urk; Terry Wiersma; Vincent Dezentje; Marie-Jeanne T F D Vrancken Peeters; Frederieke H van Duijnhoven
Journal:  Ann Surg Oncol       Date:  2021-05-12       Impact factor: 5.344

Review 3.  Surgical Management of Breast Cancer Treated with Neoadjuvant Therapy.

Authors:  Octavi Cordoba; Lourdes Carrillo-Guivernau; Carmen Reyero-Fernández
Journal:  Breast Care (Basel)       Date:  2018-07-25       Impact factor: 2.860

4.  Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.

Authors:  Y Delpech; C Coutant; L Hsu; E Barranger; T Iwamoto; C H Barcenas; G N Hortobagyi; R Rouzier; F J Esteva; L Pusztai
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

5.  Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.

Authors:  Merisa L Piper; Jasmine Wong; Kelly Fahrner-Scott; Cheryl Ewing; Michael Alvarado; Laura J Esserman; Rita A Mukhtar
Journal:  NPJ Breast Cancer       Date:  2019-09-06

6.  A nomogram for determining the disease-specific survival in invasive lobular carcinoma of the breast: A population study.

Authors:  Rong Fu; Jin Yang; Hui Wang; Lin Li; Yuzhi Kang; Rahel Elishilia Kaaya; ShengPeng Wang; Jun Lyu
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.